Selected Publications
Leonard A, Furstenau D, Abraham AA, Darbari D, Nickel RS, Limerick E, Fitzhugh CD, Hsieh M, Tisdale JF. Reduction in vaso-occlusive events following stem cell transplantation in patients with sickle cell disease. BloodAdv 7(2):227-234, 2023. doi: 10.1182/bloodadvances.2022008137
Sharma A, Leonard A, West K, Gossett JM, Uchida N, Panch S, Stroncek D, Poston L, Akel S, Hankins JS, Fitzhugh C, Hsieh MM, Kang G, Tisdale JF, Weiss MJ, Zheng Y. Optimizing haematopoietic stem and progenitor cell apheresis collection from plerixafor-mobilized patients with sickle cell disease. Br J Haematol Aug;198(4):740-744, 2022. doi: 10.1111/bjh.18311. PMID: 35737751
Leonard A, Sharma A, Uchida N, Stroncek D, Panch SR, West K, Molloy E, Hughes TE, Hauffe S, Taylor T, Fitzhugh C, Hankins JS, Wilson M, Tsai SQ, Weiss MJ, Hsieh M, Tisdale JF. Disease severity impacts plerixafor mobilized stem cell collection in patients with sickle cell disease. Blood Adv 5(9):2403–2411, 2021.
Leonard A, Bertaina A, Bonfim C, Cohen S, Prockop S, Purtill D, Russell A, Boelens JJ, Wynn R, Ruggeri A, Abraham A. Curative therapy for hemoglobinopathies: an ISCT Stem Cell Engineering Committee review comparing outcomes, accessibility, and cost of ex vivo stem cell gene therapy vs. allogeneic hematopoietic stem cell transplantation. Cytotherapy ISSN 1465-3249, 2021. https://doi.org/10.1016/j.jcyt.2021.09.003.
Leonard A, Tisdale JF. A pause in gene therapy: Reflecting on the unique challenges of sickle cell disease. Molecular Therapy. Mol Ther Apr 7;29(4):1355-1356, 2021. doi: 10.1016/j.ymthe.2021.03.010. Epub 2021 Mar 19
Uchida N, Leonard A, Stroncek D, Panch SR, West K, Molloy E, Hughes TE, Hauffe S, Taylor T, Fitzhugh C, Hankins JS, Wilson M, Sharma A, Tsai SQ, Weiss MJ, Hsieh M, Tisdale JF. Safe and efficient peripheral blood stem cell collection in patients with sickle cell disease using plerixafor. Haematologica Oct 1;105(10):236182, 2020.
Leonard A, Tisdale JF, Abraham A. Curative options for sickle cell disease: haploidentical stem cell transplantation or gene therapy? Br J Haematol May;189(3):408-423, 2020.
Demirci S, Haro-Mora JJ, Leonard A, Drysdale C, Malide D, Keyvanfar K, Essawi K, Vizcardo R, Tamaoki N, Restifo NP, Tisdale JF, Uchida N. Definitive hematopoietic stem/progenitor cells from human embryonic stem cells through serum/feeder-free organoid-induced differentiation. Stem Cell Res Ther 11:493, 2020.
Demirci S, Zeng J, Wu Y, Uchida N, Shen AH, Pellin D, Gamer J, Yapundich M, Drysdale C, Bonanno J, Bonifacino AC, Krouse AE, Linde NS, Engels T, Donahue RE, Haro-Mora JJ, Leonard A, Nassehi T, Luk K, Porter SN, Lazzarotto CR, Tsai SQ, Weiss MJ, Pruett-Miller SM, Wolfe SA, Bauer DE, Tisdale JF. BCL11A enhancer-edited hematopoietic stem cells persist in rhesus monkeys without toxicity. J Clin Invest Dec 1;130(12):6677-6687, 2020.
Leonard A, Bonifacino A, Dominical VM, Luo M, Uchida N, Pierciey FJ, Tisdale JF. Bone marrow characterization in sickle cell disease: inflammation and stress erythropoiesis lead to suboptimal CD34 recovery compared to normal volunteer bone marrow. Br J Haematol Jul;186(2):286-299, 2019.
Uchida N, Nassehi T, Drysdale CM, Gamer J, Yapundich M, Demirci S, Haro-Mora JJ, Leonard A, Hsieh MM, Tisdale JF. High-Efficiency Lentiviral Transduction of Human CD34+ Cells in High-Density Culture with Poloxamer and Prostaglandin E2. Mol Ther Methods Clin Dev Jan 25;13:187-196, 2019.
Leonard A, Tisdale JF. Stem cell transplantation in sickle cell disease: therapeutic potential and challenges faced. Expert Rev Hematol. Expert Rev Hematol Jul;11(7):547-565, 2018.
Leonard A, Godiwala N, Herrera N, McCarter R, Sharron M, Meier E. The use of inhaled corticosteroids for prevention of acute morbidity in patients with sickle cell disease and acute chest syndrome. Blood Cells Mol Dis Jul;71:55-62, 2018.
Last update: August 2023